 SALT LAKE CITY, June 18, 2021 PRNewswire -- Co-Diagnostics, Inc. Nasdaq: CODX, a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix SmartTM SARS-CoV-2 DS Direct Saliva has obtained regulatory authorization to be sold as an in vitro diagnostic IVD for the diagnosis of COVID-19 in markets that accept CE markings, and is now available for purchase from the Companys Utah-based ISO-13485:2016 certified facility. Co-Diagnostics Logix Smart DS test kit is designed to detect the presence of the RdRp and E genes of SARS-CoV-2 directly from minimally processed human saliva samples while eliminating RNA extraction of the samples, a costly and time-consuming process required by most PCR tests. 